Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2001 Oct;85(10):1220–1224. doi: 10.1136/bjo.85.10.1220

A role for methotrexate in the management of non-infectious orbital inflammatory disease

J Smith 1, J Rosenbaum 1
PMCID: PMC1723732  PMID: 11567968

Abstract

AIM—To evaluate the clinical usefulness of methotrexate for patients with non-infectious orbital inflammatory disease who fail to respond to systemic corticosteroids and/or orbital irradiation.
METHODS—The medical records of patients with non-infectious orbital inflammatory disease who were treated with methotrexate at Oregon Health Sciences University between June 1993 and June 2000 were examined. Methotrexate was administered at a median maximum dose of 20 mg per week (range 15-25 mg per week) in conjunction with folate supplementation. Patients were followed with regular ophthalmic examinations, as well as serum liver enzyme levels and blood cell counts. Clinical signs of regression of the orbital inflammation, visual acuity, dosage and duration of methotrexate therapy, requirement for concurrent corticosteroid administration, and adverse drug reactions were recorded.
RESULTS—The study cohort included 14 patients (24 eyes) with diagnoses including non-specific orbital inflammation (n=7), Tolosa-Hunt syndrome (n=1), thyroid orbitopathy (n=3), Wegener's granulomatosis (n=1), sarcoidosis (n=1), and Erdheim-Chester disease (n=1). In all cases, methotrexate was commenced as a corticosteroid sparing agent. 10 patients (71%) completed a 4 month therapeutic trial of methotrexate. Median duration of treatment for the nine (64%) patients who experienced clinical benefit was 25 months (range 10-47 months). Six responders were ultimately able to cease methotrexate, including the single patient who required concurrent long term corticosteroid therapy. Complications included fatigue, gastrointestinal disturbance, hair thinning and mild, reversible serum liver enzyme elevation. Two patients (14%) discontinued treatment because of adverse effects.
CONCLUSION—Methotrexate is a well tolerated immunosuppressive medication which may benefit patients with recalcitrant non-infectious orbital inflammatory disease.



Full Text

The Full Text of this article is available as a PDF (106.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dev S., McCallum R. M., Jaffe G. J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999 Jan;106(1):111–118. doi: 10.1016/S0161-6420(99)90011-8. [DOI] [PubMed] [Google Scholar]
  2. Foster C. S. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980 Feb;87(2):140–150. doi: 10.1016/s0161-6420(80)35272-x. [DOI] [PubMed] [Google Scholar]
  3. Holz F. G., Krastel H., Breitbart A., Schwarz-Eywill M., Pezzutto A., Völcker H. E. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol. 1992;1(3-4):142–144. [PubMed] [Google Scholar]
  4. Jabs D. A., Rosenbaum J. T., Foster C. S., Holland G. N., Jaffe G. J., Louie J. S., Nussenblatt R. B., Stiehm E. R., Tessler H., Van Gelder R. N. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492–513. doi: 10.1016/s0002-9394(00)00659-0. [DOI] [PubMed] [Google Scholar]
  5. Kremer J. M., Alarcón G. S., Lightfoot R. W., Jr, Willkens R. F., Furst D. E., Williams H. J., Dent P. B., Weinblatt M. E. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar;37(3):316–328. doi: 10.1002/art.1780370304. [DOI] [PubMed] [Google Scholar]
  6. Kremer J. M., Kaye G. I., Kaye N. W., Ishak K. G., Axiotis C. A. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum. 1995 Sep;38(9):1194–1203. doi: 10.1002/art.1780380904. [DOI] [PubMed] [Google Scholar]
  7. Kremer J. M., Phelps C. T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992 Feb;35(2):138–145. doi: 10.1002/art.1780350203. [DOI] [PubMed] [Google Scholar]
  8. Langford C. A., Sneller M. C., Hoffman G. S. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am. 1997 Nov;23(4):841–853. doi: 10.1016/s0889-857x(05)70363-x. [DOI] [PubMed] [Google Scholar]
  9. Leone C. R., Jr, Lloyd W. C., 3rd Treatment protocol for orbital inflammatory disease. Ophthalmology. 1985 Oct;92(10):1325–1331. doi: 10.1016/s0161-6420(85)33854-x. [DOI] [PubMed] [Google Scholar]
  10. Leone C. R., Jr The management of ophthalmic Graves' disease. Ophthalmology. 1984 Jul;91(7):770–779. doi: 10.1016/s0161-6420(84)34221-x. [DOI] [PubMed] [Google Scholar]
  11. Messmer E. M., Foster C. S. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea. 1995 Jul;14(4):408–417. doi: 10.1097/00003226-199507000-00010. [DOI] [PubMed] [Google Scholar]
  12. Mombaerts I., Schlingemann R. O., Goldschmeding R., Koornneef L. Are systemic corticosteroids useful in the management of orbital pseudotumors? Ophthalmology. 1996 Mar;103(3):521–528. doi: 10.1016/s0161-6420(96)30663-5. [DOI] [PubMed] [Google Scholar]
  13. Perry S. R., Rootman J., White V. A. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology. 1997 Apr;104(4):683–694. doi: 10.1016/s0161-6420(97)30251-6. [DOI] [PubMed] [Google Scholar]
  14. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol. 1999 May;11(3):226–232. doi: 10.1097/00002281-199905000-00012. [DOI] [PubMed] [Google Scholar]
  15. Shah S. S., Lowder C. Y., Schmitt M. A., Wilke W. S., Kosmorsky G. S., Meisler D. M. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992 Sep;99(9):1419–1423. doi: 10.1016/s0161-6420(92)31790-7. [DOI] [PubMed] [Google Scholar]
  16. Shetty A. K., Zganjar B. E., Ellis G. S., Jr, Ludwig I. H., Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus. 1999 May-Jun;36(3):125–128. doi: 10.3928/0191-3913-19990501-09. [DOI] [PubMed] [Google Scholar]
  17. Smitt M. C., Donaldson S. S. Radiation therapy for benign disease of the orbit. Semin Radiat Oncol. 1999 Apr;9(2):179–189. doi: 10.1016/s1053-4296(99)80008-3. [DOI] [PubMed] [Google Scholar]
  18. Stanbury R. M., Graham E. M. Systemic corticosteroid therapy--side effects and their management. Br J Ophthalmol. 1998 Jun;82(6):704–708. doi: 10.1136/bjo.82.6.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Symmons D. Excess mortality in rheumatoid arthritis--is it the disease or the drugs? J Rheumatol. 1995 Dec;22(12):2200–2202. [PubMed] [Google Scholar]
  20. Weinblatt M. E., Weissman B. N., Holdsworth D. E., Fraser P. A., Maier A. L., Falchuk K. R., Coblyn J. S. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 1992 Feb;35(2):129–137. doi: 10.1002/art.1780350202. [DOI] [PubMed] [Google Scholar]
  21. Weiss A. H., Wallace C. A., Sherry D. D. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998 Aug;133(2):266–268. doi: 10.1016/s0022-3476(98)70232-x. [DOI] [PubMed] [Google Scholar]
  22. Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., Spitz P. W., Haga M., Kleinheksel S. M., Cathey M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481–494. doi: 10.1002/art.1780370408. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES